Streetbeat News

Stock Prices

BRK-A

HAL

ORCL

CNBC's 'Halftime Report Final Trades' mentioned Oracle Corporation, Berkshire Hathaway Inc., Zoom Video Communications, Inc., and Halliburton Company. Oracle is expected to report quarterly earnings of $1.14 per share on revenue of $12.46 billion. Berkshire Hathaway’s shares jumped 16% over the past six months. Zoom announced that its AI assistant will now be included for customers with paid services at no additional cost. Halliburton reported second-quarter FY23 revenue growth of 14.3% year-over-year to $5.798 billion, missing the consensus of $5.86 billion.

Portfolio Pulse from Lisa Levin

September 08, 2023 | 12:47 pm

MARA

Marathon Digital Holdings, Inc. (NASDAQ:MARA) has announced private exchanges of approximately $417 million of its 1.00% Convertible Senior Notes due 2026 for about 26.2 million newly issued shares of common stock. The company will not receive any cash proceeds from the issuance of the shares. The final number of shares to be issued will be determined over a number of days. The exchanges could affect the market price of Marathon's common stock.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:46 pm

APP

BASE

NTNX

PATH

WDAY

The article lists five tech stocks that are considered overbought and may crash in September. These include Couchbase, Inc. (NASDAQ:BASE), UiPath Inc. (NYSE:PATH), AppLovin Corporation (NASDAQ:APP), Workday, Inc. (NASDAQ:WDAY), and Nutanix, Inc. (NASDAQ:NTNX). The Relative Strength Index (RSI) values for these stocks are above 70, indicating they are overbought.

Portfolio Pulse from Lisa Levin

September 08, 2023 | 12:45 pm

CALT

TVTX

XBI

Swedish biopharma Calliditas Therapeutics AB (NASDAQ:CALT) is making progress in addressing rare kidney diseases with its lead drug, Tarpeyo. The drug has received accelerated FDA approval for treating IgA nephropathy, an autoimmune kidney disorder. Tarpeyo focuses on the origin of the disease and is delivered to the gut. The CEO of Calliditas, Renee Aguiar-Lucander, highlighted two key differentiators for Tarpeyo versus other approaches in chronic kidney disease treatment. The drug can stabilize kidney function and gives the freedom of not necessarily staying on it for the rest of a patient's life. The company is also close to profitability and has a healthy cash balance.

Portfolio Pulse from Shanthi Rexaline

September 08, 2023 | 12:42 pm

IMPL

Impel Pharmaceuticals has entered into a second amendment to its credit agreement, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:40 pm

BIOC

GROM

SNOW

Plus Therapeutics licenses diagnostic assay to detect central nervous system cancers, causing BIOC to rise by 79%. DA Davidson initiates coverage on Snowflake with a buy rating and a price target of $200, leading to a 3% increase in SNOW. Grom Social Enterprises announces pricing of $3M public offering of 946,000 units at $3.00 per unit, resulting in a 53% drop in GROM.

Portfolio Pulse from ryanfaloona@benzinga.com

September 08, 2023 | 12:39 pm

ZVSA

HC Wainwright has initiated coverage on ZyVersa Therapeutics with a Buy rating and a price target of $2.5. This has led to an increase in the trading of ZyVersa shares.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:38 pm

FXY

Invesco CurrencyShares Japanese Yen Trust (NYSE:FXY), an ETF that tracks the Japanese yen, traded higher on Thursday. The ETF saw more than 8x its average daily call volume. A buyer purchased 1,180 of the January 2025 66-calls at an average price of $3.77 per contract. The trader expects FXY to trade above the $70 mark in just over a year.

Portfolio Pulse from Lisa Levin

September 08, 2023 | 12:38 pm

BIOC

Biocept has entered into a non-exclusive licensing agreement for CNSide with Plus Therapeutics. This news has led to an increase in Biocept's share prices.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:36 pm

BREZ

Breeze Holdings Acquisition Corp. (NASDAQ:BREZ) has announced that it has received proxies representing approximately 75.8% of the company's total outstanding shares to approve the proposal to extend the date by which the company must consummate a business combination until as late as June 26, 2024. The company has entered into a merger agreement with TV Ammo, Inc., and upon closing of the transaction, the company will be renamed 'True Velocity, Inc.' and its common stock is expected to trade on the Nasdaq Capital Market. The transaction is now expected to close in the first quarter of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:32 pm